SAN FRANCISCO and SUZHOU, China, Jan. , PRNewswire Innovent Biologics, Inc. HKEX: "Innovent", a worldclass biopharmaceutical company committed to developing, manufacturing and commercializing high quality medicines for oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that it has entered into an exclusive global collaboration and license agreement with Roche SIX: RO, ROG; OTCQX: RHHBY to advance the development of IBI, a nextgeneration antibodydrug conjugate ADC candidate targeting deltalike ligand DLL, to provide a new treatment option for patients with advanced small cell lung cancer SCLC. IBI has obtained clinical application IND approval in Australia, China and the United States, and the first patient was dosed in the Phase I clinical study in December .
IBI specifically targets DLL, an antigen that is lowly expressed in normal tissues switzerland phone number list but significantly overexpressed in certain cancer types, especially SCLC and other neuroendocrine tumors. As one of the potential bestinclass and leading DLLtargeted ADCs, IBI is designed and developed based on Innovent's proprietary novel topoisomerase I inhibitor TOPOi platform. IBI has demonstrated encouraging antitumor activity in multiple tumor burden mouse models, especially in chemotherapyresistant tumor types, and has a favorable safety profile.